Login to Your Account

FDA Panel Says Gene Therapy For SCID Should Be Last Resort

By Kim Coghill

Monday, March 3, 2003
SILVER SPRING, Md. - Development of leukemia in two French gene therapy patients coupled with limited data prompted an FDA panel of advisers to conclude that gene therapy trials in X-linked severe combined immunodeficiency (SCID) should not go forward unless there are no other treatment options available. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription